A, achievement of hemostasis in AHA is difficult because of the reduced efficacy of standard FVIII replacement products and need for bypassing agent administration in many patients. The management of AHA-related bleeding is particularly challenging in patients with coronary artery disease (CAD) because of the increased risk of thromboembolism associated with the administration of bypassing agents. 5, 6 This case report examines the Key Clinical Question of how to manage in-stent restenosis in a patient with refractory AHA.
| CASE
Our patient is a 72-year-old male with a history of bullous pemphig- 
| DISCUSSION
AHA is a rare coagulopathy that preferentially affects older individuals who are also at greater risk for cardiovascular disease.
Immunosuppression is first-line therapy for AHA, and although the majority of patients with AHA achieve a complete remission with immunosuppressive therapy (71% in the United Kingdom Hemophilia Centre Doctor's Organization registry), a significant proportion relapse or are refractory despite multiple attempts at inhibitor eradication. 2 Therefore, it is likely that hematologists will care for patients with refractory FVIII inhibitors and age-related cardiovascular events.
Several methods should be employed in this population to reduce procedural-related bleeding. The use of radial access over femoral access has proven to decrease procedural bleeding by 30% in the general population and has increasingly become the access of choice for PCI. [9] [10] [11] [12] [13] The use of a BMS over DES is also recommended to limit the duration of DAPT. 12, 13 However, BMSs are associated with significantly higher rates of in-stent restenosis compared to DES-a complication that led to our patient's second presentation and need for further intervention to restore patency to the mid-LAD stent. 14 Additionally, when P2Y 12 inhibitor therapy is indicated, relative platelet inhibition potency among available agents should be considered to minimize bleeding. 12, 15, 16 For our patient, radial access was used, and clopidogrel was chosen over more potent P2Y 12 inhibitors associated with higher bleeding risk. However, a DES was placed due to the location of the coronary lesion and the prior failure of a BMS.
Although bypassing therapies are effective for management of most acute bleeding events, 17 In patients with AHA successfully undergoing inhibitor eradication, thromboembolic risk may increase as FVIII inhibitor titers decline and FVIII levels normalize.
In conclusion, we present a patient with AHA refractory to multiple immunosuppressive regimens presenting with ACS requiring PCI who was successfully managed with emicizumab. We believe this
